Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
CA 2228176 C · Owner: Northwest Biotherapeutics, Inc. · Inventors: Tjoa, Benjamin A.; Boynton, Alton L.; Murphy, Gerald P.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Methods and compositions for use of human dendritic cells to activate T cells for immunotherapeutic responses against primary and metastatic prostate cancer are disclosed. In one embodiment, human dendritic cells after exposure to a , prostate cancer antigen or specific antigenic peptide are administered to a , prostate cancer patient to activate the relevant T cell responses in vivo. In an alternate embodiment, human dendritic cells are exposed to a prostate cancer antigen or specific antigenic peptide in vitro and incubated or cultured with primed or unprimed T cells to activate the relevant T cell responses in vitro. The activated T cells are then administered to a prostate cancer …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 29, 1996 and granted May 26, 2015. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 29, 2016.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 29, 2018.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.